The Alzheimer's disease Beta-secretase enzyme, BACE1
Open accessThe DOI matches its Crossref record; 253 of the 254 references it cites were found in a registry or an index.
Abstract
The pathogenesis of Alzheimer's disease is highly complex. While several pathologies characterize this disease, amyloid plaques, composed of the beta-amyloid peptide are hallmark neuropathological lesions in Alzheimer's disease brain. Indeed, a wealth of evidence suggests that beta-amyloid is central to the pathophysiology of AD and is likely to play an early role in this intractable neurodegenerative disorder. The BACE1 enzyme is essential for the generation of beta-amyloid. BACE1 knockout mice do not produce beta-amyloid and are free from Alzheimer's associated pathologies including neuronal loss and certain memory deficits. The fact that BACE1 initiates the formation of beta-amyloid, and the observation that BACE1 levels are elevated in this disease provide direct and compelling reasons to develop therapies directed at BACE1 inhibition thus reducing beta-amyloid and its associated toxicities. However, new data indicates that complete abolishment of BACE1 may be associated with specific behavioral and physiological alterations. Recently a number of non-APP BACE1 substrates have been identified. It is plausible that failure to process certain BACE1 substrates may underlie some of the reported abnormalities in the BACE1-deficient mice. Here we review BACE1 biology, covering aspects ranging from the initial identification and characterization of this enzyme to recent data detailing the apparent dysregulation of BACE1 in Alzheimer's disease. We pay special attention to the putative function of BACE1 during healthy conditions and discuss in detail the relationship that exists between key risk factors for AD, such as vascular disease (and downstream cellular consequences), and the pathogenic alterations in BACE1 that are observed in the diseased state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 The intracellular trafficking of BACE1. (1) Following synthesis in the ER, pro-BACE1 traffics to the Golgi. Here, the propeptide is removed and BACE1 undergoes significant post-translational modifications. The trafficking and localization of BACE1 appear dependent on the ACDL motif, composed of DISLL residues, in its C-terminal tail. Importantly, phosphorylation of the serine 498 residue (S498) is important for binding of BACE1 to the GGA monomeric adaptor proteins which are implicated in the sorting of cargo between the TGN and endosomes and vice versa [127-131], in addition to the Golgi complex to the endosomes [130]. (2) BACE1 traffics to the plasma membrane and while the re-internalization of BACE1 from the cell surface appears to be independent of the phosphorylation state of S498 [131], it has been reported that the di-leucine residues are important for BACE1 endocytosis [126]. Non-phosphorylated BACE1 may recycle from the endosome back to the cell surface [131]. However, BACE1 phosphorylated at the S498 site interacts with GGA1 in the endosome and traffics back to the TGN [131], and (3) the interaction of phosphorylated BACE1 with GGA3 appears to direct BACE1 to the lysosome, where it is degraded [135]. In addition to S498 phosphorylation, the di-leucine residues are also important for the sorting of BACE1 into lysosomal compartments [140]. BACE1 is also degraded in the proteasome [133]. The precise subcellular localization (early verses late endosomes) of the BACE1-GGA complex requires determination, and while it appears likely that BACE1 can traffic from the TGN to the endosome directly, it remains to be demonstrated experimentally.](https://figures.cochat.ai/paper-figures/ababb34006ec42cebddaefb7cf4bc47b/the-alzheimer-s-disease-beta-secretase-enzyme-bace1-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abnormal activation of microglia and astrocytes is observed in the brains of AD patients15 and APPPS1–21 transgenic model mice13.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Activated microglia surround amyloid plaques in the brains of both human patients with AD and mouse models of Aβ amyloidosis13,15,21,22.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
2 retracted
Items 201–253 of 253
Translational regulation of BACE-1 expression in neuronal and non-neuronal cells
De Pietri Tonelli, D. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh348 · Cited by 81
Interferon γ stimulates β-secretase expression and sAPPβ production in astrocytes
Hong, H. S., Hwang, E. M., Sim, H. J., Cho, H.-J., Boo, J. H., Oh, S. S., Kim, S. U., & Mook-Jung, I. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01270-1 · Cited by 81 · cited 2×
“Proinflammatory cytokines such as interferon γ (IFNγ), tumor necrosis factor α (TNFα) and interleukin β (IL1β) have been shown to increase Aβ secretion in cultured human astrocytes and astrocytic cell lines [90], and BACE1 levels rise, at least with IFNγ treatment [91,92].”
Haass, C., Capell, A., Citron, M., Teplow, D. B., & Selkoe, D. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6186 · Cited by 80
In Vivo Cleavage of α2,6-Sialyltransferase by Alzheimer β-Secretase
Kitazume, S., Nakagawa, K., Oka, R., Tachida, Y., Ogawa, K., Luo, Y., Citron, M., Shitara, H., Taya, C., Yonekawa, H., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409417200 · Cited by 79
Caspase-Mediated Degeneration in Alzheimer's Disease
Cribbs, D. H., Poon, W. W., Rissman, R. A., & Blurton-Jones, M. M. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63302-0 · Cited by 79
Xiong, K., Cai, H., Luo, X.-G., Struble, R. G., Clough, R. W., & Yan, X.-X. (2007) · Experimental Brain Research · doi:10.1007/s00221-007-0943-y · Cited by 79
Human BACE Forms Dimers and Colocalizes with APP
Schmechel, A., Strauss, M., Schlicksupp, A., Pipkorn, R., Haass, C., Bayer, T. A., & Multhaup, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402785200 · Cited by 79
β-Site APP Cleaving Enzyme mRNA Expression in APP Transgenic Mice
Irizarry, M. C., Locascio, J. J., & Hyman, B. T. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63955-7 · Cited by 77
Function and Dysfunction of the Presenilins
Sisodia, S. S., Kim, S. H., & Thinakaran, G. (1999) · The American Journal of Human Genetics · doi:10.1086/302475 · Cited by 76 · cited 1×
“A strong genetic correlation exists between FAD and the 42 amino acid Aβ form (Aβ42; reviewed in [12-14]).”
Vance, J. E., Karten, B., & Hayashi, H. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340399 · Cited by 75
Harada, H., Tamaoka, A., Ishii, K., Shoji, S., Kametaka, S., Kametani, F., Saito, Y., & Murayama, S. (2005) · Neuroscience Research · doi:10.1016/j.neures.2005.10.001 · Cited by 75
Vascular disorder in Alzheimer’s disease: role in pathogenesis of dementia and therapeutic targets
Zloković, B. V. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00150-3 · Cited by 74
Rapoport, S. I. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/pl00014174 · Cited by 69
Rockwood, K. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00688.x · Cited by 68
Detection of a Soluble Form of BACE-1 in Human Cerebrospinal Fluid by a Sensitive Activity Assay
Verheijen, J. H., Huisman, L. G., van Lent, N., Neumann, U., Paganetti, P., Hack, C. E., Bouwman, F., Lindeman, J., Bollen, E. L., & Hanemaaijer, R. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.066720 · Cited by 67
Apical Sorting of β-Secretase Limits Amyloid β-Peptide Production
Capell, A., Meyn, L., Fluhrer, R., Teplow, D. B., Walter, J., & Haass, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109119200 · Cited by 67
Closing in on the Amyloid Cascade
Doms, R. W., & Huse, J. T. (2000) · Molecular Neurobiology · doi:10.1385/mn:22:1-3:081 · Cited by 67
Lleó, A., Waldron, E., von Arnim, C. A. F., Herl, L., Tangredi, M. M., Peltan, I. D., Strickland, D. K., Koo, E. H., Hyman, B. T., Pietrzik, C. U., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413969200 · Cited by 67
Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome
Sun, X., Tong, Y., Qing, H., Chen, C.-H., & Song, W. (2006) · The FASEB Journal · doi:10.1096/fj.05-5628com · Cited by 63
PAR-4 Is Involved in Regulation of β-Secretase Cleavage of the Alzheimer Amyloid Precursor Protein
Xie, J., & Guo, Q. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411933200 · Cited by 60
Hussain, I., Hawkins, J., Shikotra, A., Riddell, D. R., Faller, A., & Dingwall, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304186200 · Cited by 60
Bodendorf, U., Fischer, F., Bodian, D., Multhaup, G., & Paganetti, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008861200 · Cited by 58
Expression of β-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology
Bigl, M., Apelt, J., Luschekina, E. A., Lange‐Dohna, C., Roßner, S., & Schliebs, R. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01452-x · Cited by 57
Hypertension and Related Factors in the Etiology of Alzheimer's Disease
SKOOG, I., & GUSTAFSON, D. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04796.x · Cited by 57
GGA1 Acts as a Spatial Switch Altering Amyloid Precursor Protein Trafficking and Processing
von Arnim, C. A. F., Spoelgen, R., Peltan, I. D., Deng, M., Courchesne, S., Koker, M., Matsui, T., Kowa, H., Lichtenthaler, S. F., Irizarry, M. C., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2290-06.2006 · Cited by 57
Insights into the Phosphoregulation of β‐Secretase Sorting Signal by the VHS Domain of GGA1
Shiba, T., Kametaka, S., Kawasaki, M., Shibata, M., Waguri, S., Uchiyama, Y., & Wakatsuki, S. (2004) · Traffic · doi:10.1111/j.1600-0854.2004.00188.x · Cited by 56
Cloning and expression of the rat BACE1 promoter
Lange‐Dohna, C., Zeitschel, U., Gaunitz, F., Perez‐Polo, J. R., Bigl, V., & Roßner, S. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10639 · Cited by 55
Ge, Y.-W., Maloney, B., Sambamurti, K., & Lahiri, D. K. (2004) · The FASEB Journal · doi:10.1096/fj.03-1379fje · Cited by 55
Leuba, G., Wernli, G., Vernay, A., Kraftsik, R., Mohajeri, M. H., & Saini, K. D. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000083496 · Cited by 53
Sauder, J. M., Arthur, J. W., & Dunbrack, R. L. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3860 · Cited by 52
Proteomics‐driven progress in neurodegeneration research
Fountoulakis, M., & Kossida, S. (2006) · ELECTROPHORESIS · doi:10.1002/elps.200500738 · Cited by 51
Splice variants of the β-site APP-cleaving enzyme BACE1 in human brain and pancreas
Ehehalt, R., Michel, B., De Pietri Tonelli, D., Zacchetti, D., Simons, K., & Keller, P. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00169-9 · Cited by 51
Is Alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion?
de la Torre, J. C. (2005) · Annals of Neurology · doi:10.1002/ana.20516 · Cited by 49
Severe cardiovascular disease and Alzheimer's disease: Senile plaque formation in cortical areas
Soneira, C. F., & Scott, T. M. (1996) · Clinical Anatomy · doi:10.1002/(sici)1098-2353(1996)9:2<118::aid-ca4>3.0.co;2-d · Cited by 47
Sheng, J. G., Price, D. L., & Koliatsos, V. E. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.08.018 · Cited by 47
Huse, J. T., Byant, D., Yang, Y., Pijak, D. S., D'Souza, I., Lah, J. J., Lee, V. M.-Y., Doms, R. W., & Cook, D. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213303200 · Cited by 42
Atherosclerosis and Neurodegeneration: Unexpected Conspirators in Alzheimer’s Dementia
Iadecola, C. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000102660.99744.85 · Cited by 42
Prodomain processing of Asp1 (BACE2) is autocatalytic
Hussain, I., Christie, G., Schneider, K., Moore, S., & Dingwall, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101069200 · Cited by 41 · cited 1×
“Unlike BACE1, pro-BACE2 requires autocatalytic pro-domain processing for enzymatic activation [75].”
Wickham, L., Benjannet, S., Marcinkiewicz, E., Chretien, M., & Seidah, N. G. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02840.x · Cited by 37
RAPOPORT, S. I. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07823.x · Cited by 37
The Functions of the Amyloid Precursor Protein Gene
Panegyres, P. K. (2001) · Reviews in the Neurosciences · doi:10.1515/revneuro.2001.12.1.1 · Cited by 36
Yan, X., Xiong, K., Luo, X., Struble, R. G., & Clough, R. W. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21239 · Cited by 36
Akkawi, N. M., Borroni, B., Agosti, C., Magoni, M., Broli, M., Pezzini, A., & Padovani, A. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0689-z · Cited by 35
Ohno, M. (2006) · Reviews in the Neurosciences · doi:10.1515/revneuro.2006.17.4.429 · Cited by 32
Guo, Z., Qiu, C., Viitanen, M., Fastbom, J., Winblad, B., & Fratiglioni, L. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3609 · Cited by 29
Extracellular release of BACE1 holoproteins from human neuronal cells
Murayama, K. S., Kametani, F., & Araki, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.015 · Cited by 26
Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results
Santa, W. (2005) · Dkgest of the World Latest Medical Information · Cited by 26
Lindholm, T., Cullheim, S., Deckner, M., Carlstedt, T. P., & Risling, M. (2002) · Experimental Brain Research · doi:10.1007/s00221-001-0922-7 · Cited by 24
Lahiri, D., Ge, Y.-W., Rogers, J., Sambamurti, K., Greig, N., & Maloney, B. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025224 · Cited by 24
Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study
Etminan, M., & Fitzgerald, A. S. M. (2019) · Cited by 21
A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's β-secretase.
Bennett, B. D., Denis, P., Haniu, M., Teplow, D. B., Kahn, S., Louis, J., Citron, M., & Vassar, R. J. (2001) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)56862-4 · Cited by 5
Self-citation10. Genetics of Alzheimer's disease
Hutton, M. L., Pérez‐Tur, J., & Hardy, J. (2017) · Princeton University Press eBooks · doi:10.2307/j.ctv3hh4x0.15 · Cited by 5
Roßner, S., Apelt, J., Schliebs, R., et al. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1095.abs · Cited by 1
Research works printed but not linked: 2
- Golde TE, Dickson D, Hutton M: Filling the gaps in the abeta cas- cade hypothesis of Alzheimer's disease. Curr Alzheimer Res 2006, 3(5):421-430.
- Hong HS, Hwang EM, Sim HJ, Cho HJ, Boo JH, Oh SS, Kim SU, Mook- Jung I: Interferon gamma stimulates beta-secretase expres- sion and sAPPbeta production in astrocytes. Biochem Biophys Res Commun 2003, 307(4):922-927.
Cited by
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626
Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
Sadigh-Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., & Mahmoudi, J. (2015) · Medical Principles and Practice · doi:10.1159/000369101 · Cited by 537
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Metadata
- Authors
- Cole, S. L., & Vassar, R.
- Affiliations
- Northwestern University (US)
- Corresponding author
- Vassar, Robert
- ORCID
- Vassar, Robert
- Venue
- Molecular Neurodegeneration
- Published
- 2007
- Volume
- 2
- Issue
- 1
- Pages
- 22
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC2211305
- OpenAlex
- W2129495914
- Cited by
- 550
- References
- 254
- Citations by year
- 2026: 27 · 2025: 53 · 2024: 45 · 2023: 46 · 2022: 27 · 2021: 40 · 2020: 32 · 2019: 30 · 2018: 20 · 2017: 25 · 2016: 31 · 2015: 25 · 2014: 27 · 2013: 27 · 2012: 23
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- John Douglas French Alzheimer's Foundation
- National Institute on Aging (P01AG021184)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, BACE1, beta-secretase, amyloid-beta, amyloid plaques, BACE1 inhibition, vascular disease, Alzheimer's disease risk factors, neurodegeneration, memory impairment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.